), so will our ability to design and develop cancer therapies based on disease/tissue-specific relationships between p53, MDM2 and MDMX (see reviews by Nguyen et al. and Burgess et al. for detailed overview of therapies targeting MDM2/MDMX-p53) (Burgess et al., 2016; Nguyen et al., 2017; Klein et al., 2021). This evidence concerns the gene MDM4 and cancer.